Can Paxil Cause Elevated AST/ALT?
Yes, Paxil (paroxetine) can cause elevated liver transaminases (AST/ALT), though this occurs infrequently and is typically mild and reversible upon discontinuation.
Evidence from FDA Drug Labeling
The official FDA labeling for Paxil provides direct evidence of hepatotoxicity 1:
In elderly patients with major depressive disorder: 3 of 104 patients treated with Paxil CR experienced liver transaminase elevations of potential clinical concern, compared to none of 109 placebo patients. Two patients discontinued treatment due to abnormal liver function tests, while the third patient's transaminases normalized with continued treatment 1.
In panic disorder trials: 4 of 444 patients on Paxil CR (versus 0 of 445 on placebo) developed transaminase elevations of potential clinical concern. All 4 patients showed substantial decreases after discontinuing Paxil CR 1.
In general controlled trials: Patients treated with Paxil exhibited abnormal liver function tests at rates comparable to placebo, with no significant differences in alkaline phosphatase, SGOT (AST), SGPT (ALT), or bilirubin 1.
Clinical Significance and Pattern
The hepatotoxicity pattern with paroxetine appears to be:
- Frequency: Uncommon (<1% in most trials)
- Severity: Generally mild to moderate elevations
- Reversibility: Transaminases typically decrease substantially or normalize after discontinuation
- Time course: Can occur during treatment but resolves with drug cessation
Practical Monitoring Recommendations
While routine liver enzyme monitoring is not mandated for all patients on Paxil, consider checking baseline and periodic liver function tests in:
- Patients with pre-existing liver disease
- Elderly patients (higher risk demonstrated in trials)
- Patients on multiple hepatotoxic medications
- Those developing symptoms suggestive of liver injury (fatigue, nausea, right upper quadrant pain, jaundice)
Important Caveats
The clinical significance of these findings remains uncertain 1. Most elevations are asymptomatic and discovered incidentally. The FDA labeling explicitly states that in placebo-controlled trials with immediate-release paroxetine, patients exhibited abnormal liver function tests at no greater rate than placebo-treated patients 1.
If liver enzyme elevations occur: Discontinue paroxetine if transaminases rise significantly (particularly if accompanied by symptoms or bilirubin elevation), as this typically leads to normalization of liver enzymes 1.
The risk appears real but low, and the hepatotoxicity is generally reversible, making paroxetine a reasonable choice when clinically indicated, with appropriate monitoring in higher-risk populations.